Marblegate Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Marblegate Acquisition (GATE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Marblegate Acquisition's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Marblegate Acquisition Corp | - | - | - | No |
| Competitors combined (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GATE Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Heron Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Marblegate Acquisition's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Marblegate Acquisition's Comment on Competition and Industry Peers
Publicly Traded Peers of Marblegate Acquisition Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Marblegate Acquisition Corp | 431.61 | - |
| Heron Therapeutics Inc | 58.24 | 151.51 |
| SUBTOTAL | 489.85 | 151.51 |
Sources: Marblegate Acquisition Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Marblegate Acquisition Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Marblegate Acquisition's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Marblegate Acquisition Corp | 432 | - | - |
| Heron Therapeutics Inc | 58 | 1,183,648 | -266,008 |
| PEERS TOTAL | 58 | 1,183,648 | -266,008 |
Marblegate Acquisition's Position in Industry Market Structure
Market-capitalization share and concentration across all 183 companies in Marblegate Acquisition's industry classification, broader than the peer set above. Market cap in millions of $.Marblegate Acquisition ranks #0 of 183 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 119, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Dutch Oven Gold Group Inc | 1,730 | 5.61 % |
| 2 | Jaws Mustang Acquisition Corporation | 940 | 3.05 % |
| 3 | Mntn Inc | 816 | 2.64 % |
| 4 | Constellation Acquisition Corp I | 677 | 2.19 % |
| 5 | Drugs Made In America Acquisition Ii Corp | 1,234 | 5.2% |
| 6 | Cantor Equity Partners Iv Inc | 1,234 | 5.2% |
| 7 | Sound Point Acquisition Corp I Ltd | 1,234 | 5.2% |
| 8 | American Exceptionalism Acquisition Corp A | 1,234 | 5.2% |
| 9 | Gores Holdings X Inc | 1,234 | 5.2% |
| 10 | Aldel Financial Ii inc | 1,234 | 5.2% |
| 0 | Marblegate Acquisition Corp | 432 | 0.00 % |
Market cap and industry share for the rest of Marblegate Acquisition's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-04-06.
Marblegate Acquisition's Valuation vs Competitive Position
Valuation multiples vs the Blank Checks industry average (68 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Blank Checks industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 45.2x | - |
| EV / EBITDA | - | 26.4x | - |
| P/B | -5.6x | 6.7x | -12.3x |
| Return on Equity | 10.36 % | industry aggregate | -2.64 % |
| Return on Invested Capital | 14.27 % | 0.96 % (avg) | 13.31 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Marblegate Acquisition's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | - | -0.78 % | 48.19 % | 14.27 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Marblegate Acquisition's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 119 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Marblegate Acquisition's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Marblegate Acquisition's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Marblegate Acquisition's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- Industry revenue growing at a healthy 27.5% median pace.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Marblegate Acquisition's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Marblegate Acquisition Corp | 0.16 | 0.25 | - |
| Heron Therapeutics Inc | 0.38 | 2.51 | 2.92 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Marblegate Acquisition's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Marblegate Acquisition Corp | Q4 2024 | - | - |
| Heron Therapeutics Inc | Q2 2026 | +3.6 % | - |
| PEERS TOTAL | +3.6 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Marblegate Acquisition's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Marblegate Acquisition Corp | Q4 2024 | - | - |
| Heron Therapeutics Inc | Q2 2026 | +28.6 % | -33.7 % |
Marblegate Acquisition's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Marblegate Acquisition Corp | - | - | - |
| Heron Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Marblegate Acquisition's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Marblegate Acquisition Corp | - | - |
| Heron Therapeutics Inc | - | 0.38 |
| PEERS AVERAGE | - | 3.23 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.